<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00698607</url>
  </required_header>
  <id_info>
    <org_study_id>EXCELLENT</org_study_id>
    <nct_id>NCT00698607</nct_id>
  </id_info>
  <brief_title>Efficacy of Xience/Promus Versus Cypher in rEducing Late Loss After stENTing</brief_title>
  <acronym>EXCELLENT</acronym>
  <official_title>Comparison of the Efficacy of Everolimus-Eluting Versus Sirolimus-Eluting Stent for Coronary Lesions</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Seoul National University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Abbott</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Boston Scientific Corporation</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Seoul National University Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Objectives&#xD;
&#xD;
        1. To evaluate the safety and long-term effectiveness of coronary stenting with the&#xD;
           Everolimus-eluting coronary stent system(EECSS) (XIENCETM V, Abbott Vascular, Santa&#xD;
           Clara, CA, PromusTM, Boston Scientific, Natick, MA), compared with the sirolimus-eluting&#xD;
           coronary stent system(SECSS) (CypherTM, Cordis Johnson &amp; Johnson, Warren, NJ) in the&#xD;
           treatment of coronary stenosis.&#xD;
&#xD;
        2. To evaluate the safety and efficacy of 6-month clopidogrel therapy compared with&#xD;
           12-month clopidogrel therapy.&#xD;
&#xD;
      Study Design: Prospective, open label, two-arm, randomized multi-center trial to test the&#xD;
      non-inferiority of EECSS compared with the SECSS, and to test the non-inferiority of 6 months&#xD;
      duration compared with 12 months duration of clopidogrel therapy. Patients will be randomized&#xD;
      in a two by two factorial manner according to the type of drug eluting stent (EECSS vs.&#xD;
      SECSS) and the duration of dual anti-platelet therapy (6 months vs. 12 months). Randomization&#xD;
      will also be stratified per hospital for the presence of DM and the presence of long lesions&#xD;
      (lesion length â‰¥ 28mm)&#xD;
&#xD;
      Patient Enrollment: 1,372 patients enrolled at 17 centers in Korea.&#xD;
&#xD;
      Patient Follow-Up: Clinical follow-up will occur at 1, 3, and 9 months, and at 1, 2, 3, 4,&#xD;
      and 5 years. Investigator or designee may conduct follow-up as telephone contacts or office&#xD;
      visits.&#xD;
&#xD;
      Primary Endpoint&#xD;
&#xD;
        -  In-segment late luminal loss (LL) at 9 months for comparison of stenting with EECSS vs.&#xD;
           SECSS.&#xD;
&#xD;
        -  Target vessel failure (TVF) (cardiac death, myocardial infarction, ischemia driven&#xD;
           target vessel revascularization) at 12 months for comparison of 6 months vs. 12 months&#xD;
           of clopidogrel therapy&#xD;
&#xD;
      Secondary Endpoint&#xD;
&#xD;
        -  All Death&#xD;
&#xD;
        -  Cardiac death&#xD;
&#xD;
        -  Myocardial infarction&#xD;
&#xD;
        -  Target vessel revascularization (TVR) (all and ischemia-driven)&#xD;
&#xD;
        -  Target lesion revascularization (TLR) (all and ischemia-driven)&#xD;
&#xD;
        -  Stent thrombosis&#xD;
&#xD;
        -  Acute success (device, lesion, and procedure)&#xD;
&#xD;
        -  Bleeding&#xD;
&#xD;
        -  Cerebrovascular accident&#xD;
&#xD;
        -  In-stent LL at 9 months&#xD;
&#xD;
        -  Angiographic pattern of restenosis at 9-month angiographic follow-up&#xD;
&#xD;
        -  In-stent and in-segment % diameter stenosis (%DS) at 9 months&#xD;
&#xD;
        -  In-stent % volume obstruction (%VO) at 9 months&#xD;
&#xD;
        -  Incomplete stent apposition post index procedure&#xD;
&#xD;
        -  Persisting incomplete stent apposition, late-acquired incomplete stent apposition,&#xD;
           aneurysm, thrombosis, and persisting dissection at 9 months&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Active, not recruiting</last_known_status>
  <start_date>June 2008</start_date>
  <completion_date type="Anticipated">April 2014</completion_date>
  <primary_completion_date type="Anticipated">April 2010</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>In-segment late luminal loss (LL) at 9 months for comparison of stenting with EECSS vs. SECSS.</measure>
    <time_frame>9 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Target vessel failure (TVF) (cardiac death, myocardial infarction, ischemia driven target vessel revascularization) at 12 months for comparison of 6 months vs. 12 months of clopidogrel therapy</measure>
    <time_frame>12 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>All death</measure>
    <time_frame>5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cardiac death</measure>
    <time_frame>5 Years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Myocardial infarction</measure>
    <time_frame>5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Target vessel revascularization (TVR) (all and ischemia-driven)</measure>
    <time_frame>5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Target lesion revascularization (TLR) (all and ischemia-driven)</measure>
    <time_frame>5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Stent thrombosis</measure>
    <time_frame>5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Acute success (device, lesion, and procedure)</measure>
    <time_frame>Index procedure</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Bleeding</measure>
    <time_frame>5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cerebrovascular accident</measure>
    <time_frame>5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>In-stent LL at 9 months</measure>
    <time_frame>9 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Angiographic pattern of restenosis at 9-month angiographic follow-up</measure>
    <time_frame>9 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>In-stent and in-segment % diameter stenosis (%DS) at 9 months</measure>
    <time_frame>9 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>In-stent % volume obstruction (%VO) at 9 months</measure>
    <time_frame>9 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incomplete stent apposition post index procedure</measure>
    <time_frame>Index procedure</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Persisting incomplete stent apposition, late-acquired incomplete stent apposition, aneurysm, thrombosis, and persisting dissection at 9 months</measure>
    <time_frame>9 months</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">1466</enrollment>
  <condition>Coronary Artery Disease</condition>
  <arm_group>
    <arm_group_label>E6</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Everolimus-eluting stent 6-month clopidogrel therapy</description>
  </arm_group>
  <arm_group>
    <arm_group_label>S6</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Sirolimus-eluting stent 6-month clopidogrel therapy</description>
  </arm_group>
  <arm_group>
    <arm_group_label>E12</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Everolimus-eluting stent 12-month clopidogrel therapy</description>
  </arm_group>
  <arm_group>
    <arm_group_label>S12</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Sirolimus-eluting stent 12-month clopidogrel therapy</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Everolimus-eluting stent (Xience or Promus)</intervention_name>
    <description>Use everolimus-eluting stent in the treatment of coronary stenosis</description>
    <arm_group_label>E12</arm_group_label>
    <arm_group_label>E6</arm_group_label>
    <other_name>Xience</other_name>
    <other_name>Promus</other_name>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Sirolimus-eluting stent (Cypher)</intervention_name>
    <description>Use sirolimus-eluting stent in the treatment of coronary stenosis</description>
    <arm_group_label>S12</arm_group_label>
    <arm_group_label>S6</arm_group_label>
    <other_name>Cypher</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>6-month clopidogrel therapy</intervention_name>
    <description>Use clopidogrel for 6 months</description>
    <arm_group_label>E6</arm_group_label>
    <arm_group_label>S6</arm_group_label>
    <other_name>Plavix</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>12-month clopidogrel therapy</intervention_name>
    <description>Use clopidogrel for 12 months</description>
    <arm_group_label>E12</arm_group_label>
    <arm_group_label>S12</arm_group_label>
    <other_name>Plavix</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        General Inclusion Criteria:&#xD;
&#xD;
          1. Subject must be at least 18 years of age.&#xD;
&#xD;
          2. Subject is able to verbally confirm understandings of risks, benefits and treatment&#xD;
             alternatives of receiving the XIENCE V EECS and he/she or his/her legally authorized&#xD;
             representative provides written informed consent prior to any study related procedure.&#xD;
&#xD;
          3. Subject must have significant coronary artery stenosis (&gt;50% by visual estimate)&#xD;
&#xD;
          4. Subject must have evidence of myocardial ischemia (e.g., stable, unstable angina,&#xD;
             recent infarction, silent ischemia, positive functional study or a reversible changes&#xD;
             in the electrocardiogram (ECG) consistent with ischemia. In subjects with coronary&#xD;
             artery stenosis &gt; 75%, evidence of myocardial ischemia does not have to be documented.&#xD;
&#xD;
          5. Subjects must be an acceptable candidate for Coronary Artery Bypass Graft (CABG)&#xD;
             surgery.&#xD;
&#xD;
        Angiographically Inclusion Criteria&#xD;
&#xD;
          1. Target lesion(s) must be located in a native coronary artery with visually estimated&#xD;
             diameter of â‰¥ 2.25 mm and â‰¤ 4.25 mm.&#xD;
&#xD;
          2. Target lesion(s) must be amenable for percutaneous coronary intervention&#xD;
&#xD;
        General Exclusion Criteria:&#xD;
&#xD;
          1. The patient has a known hypersensitivity or contraindication to any of the following&#xD;
             medications (heparin, aspirin, clopidogrel, sirolimus, everolimus, Contrast media&#xD;
&#xD;
          2. Systemic (intravenous) Sirolimus, everolimus use within 12 months.&#xD;
&#xD;
          3. Female of childbearing potential, unless a recent pregnancy test is negative, who&#xD;
             possibly plan to become pregnant any time after enrollment into this study.&#xD;
&#xD;
          4. History of bleeding diathesis or known coagulopathy (including heparin-induced&#xD;
             thrombocytopenia), or will refuse blood transfusions.&#xD;
&#xD;
          5. Gastrointestinal or genitourinary bleeding within the prior 3 months, or major surgery&#xD;
             within 2 months.&#xD;
&#xD;
          6. Current known current platelet count &lt;100,000 cells/mm3 or Hgb &lt;10 g/dL.&#xD;
&#xD;
          7. An elective surgical procedure is planned that would necessitate interruption of&#xD;
             clopidogrel during the first 12 months post enrollment.&#xD;
&#xD;
          8. Non-cardiac co-morbid conditions are present with life expectancy &lt;1 year or that may&#xD;
             result in protocol non-compliance (per site investigator's medical judgment).&#xD;
&#xD;
          9. Patients who are actively participating in another drug or device investigational&#xD;
             study, which have not completed the primary endpoint follow-up period.&#xD;
&#xD;
         10. Patients who have received any stent implantation in the target vessel prior to&#xD;
             enrollment.&#xD;
&#xD;
         11. Patients with LVEF&lt;25% or those with cardiogenic shock&#xD;
&#xD;
         12. Patients with myocardial infarction within 72 hours&#xD;
&#xD;
         13. Creatinine level â‰¥ 3.0mg/dL or dependence on dialysis.&#xD;
&#xD;
         14. Severe hepatic dysfunction (AST and ALT: 3 times upper normal reference values).&#xD;
&#xD;
        Angiographic Exclusion Criteria&#xD;
&#xD;
          1. Patients with significant left main coronary artery stenosis&#xD;
&#xD;
          2. Patients who's target lesion has in-stent restenosis at the stented segment of&#xD;
             drug-eluting stents or bare metal stents&#xD;
&#xD;
          3. Target lesions with chronic total occlusion&#xD;
&#xD;
          4. True bifurcation lesions requiring two stents&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Hyo-Soo Kim, MD, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Seoul National University Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Yangsoo Jang, MD, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Yonsei University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Jung-Han Yoon, MD, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Yonsei Univercity Wonju hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Ahn Tae-Hoon, MD, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Gachon Kil Medical Center</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Hyun-Cheol Kwon, MD, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Samsung Medical Center</affiliation>
  </overall_official>
  <overall_official>
    <last_name>In-Ho Chae, MD, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Seoul National University Bundang Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Young-Jin Choi, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hallym University Medical Center</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Kyoo-Rok Han, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Kandong Sacred heart Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Si-Hoon Park, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Ewha Women's University Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Myeong-Ho Chung, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Chonnam National University Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Hyuk-Moon Kwon, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Yonsei University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Dong-Woon Chun, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>National Health Insurance Service Ilsan Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Byung-Ok Kim, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Inje University Sanggye Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Do-Sun Lim, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Korea University Anam Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Taek-Jong Hong, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Pusan National University Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Woo-Young Chung, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Borame Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Jae-Hun Chung, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hallym University Kangnam Sacred Heart Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Seoul National University Hospital</name>
      <address>
        <city>Seoul</city>
        <state>28 Yongon Dong, Jongro Gu</state>
        <zip>110-744</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>June 2010</verification_date>
  <study_first_submitted>June 15, 2008</study_first_submitted>
  <study_first_submitted_qc>June 16, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 17, 2008</study_first_posted>
  <last_update_submitted>June 28, 2010</last_update_submitted>
  <last_update_submitted_qc>June 28, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 29, 2010</last_update_posted>
  <responsible_party>
    <name_title>Hyo-Soo, Kim</name_title>
    <organization>Seoul National University Hospital</organization>
  </responsible_party>
  <keyword>Everolimus</keyword>
  <keyword>Sirolimus</keyword>
  <keyword>drug eluting stent</keyword>
  <keyword>Clopidogrel</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Coronary Artery Disease</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sirolimus</mesh_term>
    <mesh_term>Everolimus</mesh_term>
    <mesh_term>Clopidogrel</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

